ImmunoGenesis doses 1st patient in phase 1/2 trial of IMGS-101 in combo with balstilimab & zalifrelimab to treat immune-excluded tumours: Houston Saturday, March 8, 2025, 18:00 Hr ...

Across the solid-tumor spectrum, many patients are burdened with metastatic, immune-excluded or immune-desert tumors that do not respond to checkpoint monoclonal antibodies. Systemically ...

In addition, immune T cells, typically in charge of fighting the tumor, were excluded from the tumor microenvironment, reducing the ability of the immune system to eliminate the tumor. Importantly ...